Compare 10X Genomics Inc (TXG) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vale SA — how do they compare? 10X Genomics Inc trades at $83.59 (market cap $10.07B), while Vale SA trades at $13.58 (market cap $57.32B). The key difference: Vale SA is far larger — about 5.7× 10X Genomics Inc's market cap, and Vale SA pays a 8.87% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vale SA for 109 Days on average.
| TXG | VALE | |
|---|---|---|
Market Cap | $10.07B | $57.32B |
Volume | 5,657,286 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $97.74 | $17.82 |
52-Week Low | $11.48 | $10.75 |
Typical Hold Time | 92 Days | 109 Days |
Enterprise Value | $9.59B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
VALE trades at $13.61, down 3.34% amid broader market weakness in steel producers. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1-Q2 2026. Fundamentals reveal declining revenue from $43.8B in 2022 to $38.4B in 2025, with net income margin compressing to 5.11%. Analyst consensus remains mixed with 32% buy ratings but a $16.21 price target suggesting 19% upside potential.
VALE faces headwinds from iron ore price volatility and rising operational costs, though its base metals segment shows growth potential. The current valuation at P/E 26.84 appears stretched given earnings pressure. Key risks include Brazilian regulatory exposure and cyclical commodity dependence, while the dividend yield of approximately 2.9% provides some income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
